The Oncology Institute, Inc.

NASDAQ:TOI

Medical - Care Facilities

Healthcare
$5.13 -1.40%

-$0.07 today

Market cap
$512.91M
Beta
0.41
P/E (TTM)
-121.1
EPS (TTM)
-$0.04
52W Low $2.02High $5.58

Volume 1.21M

Average 1.74M

TOI Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

The Oncology Institute, Inc.NASDAQ: TOI

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue growth accelerates

Q1 FY2026 cost of revenue of $125.74M rose 44.3% year over year, ahead of the +35.2% change in trailing-twelve-month cost of revenue. Sequentially, it rose 5.5% from the prior quarter. Over 3 fiscal years it compounded at +28.6% a year.

Context

  • Cost of revenue amounted to 84.8% of revenue in FY2025, down 1.5 pp from a year earlier.
  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +44.3% holds above the trailing-twelve-month pace of +35.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$125.74M+5.5% QoQ
Last fiscal yearDec 2025
$426.29M+25.6% YoY
LTMMar 2026
$464.88M+35.2% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+44.3%——
1 year+25.6%——
3-year CAGR+28.6%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
426.29M USD
Year-over-year change
+25.6%
4-year CAGR
+27.3%

Cost of Revenue vs competitors

How TOI compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +35.2% is the 2nd highest of 10, against a peer median of +5.6%.
  • Cost of revenue amounts to 85.2% of revenue for TOI, versus a peer median of 62.1%.
TOI Competitors
Cost of Revenue for TOI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AGLAgilon Health, Inc.LTM Mar 2026$5.98B USD-0.5%+39.0%102.7%
AUNAAuna S.A.LTM Mar 2026PEN 2.81B PEN+5.6%+20.1%62.1%
CCRNCross Country Healthcare, Inc.LTM Mar 2026$803.11M USD-19.9%-26.7%80.2%
SNDASonida Senior Living, Inc.LTM Mar 2026$534.91M USD+7028.0%+146.8%129.9%
TOIThe Oncology Institute, Inc.LTM Mar 2026$464.88M USD+35.2%+28.6%85.2%
EOLSEvolus, Inc.LTM Mar 2026$103.98M USD+17.4%+21.1%34.5%
AUTLAutolus Therapeutics plcLTM Mar 2026$102.95M USD-34.6%—111.2%
KIDSOrthoPediatrics Corp.LTM Mar 2026$65.51M USD+13.4%+26.3%26.9%
TMCITreace Medical Concepts, Inc.LTM Mar 2026$42.05M USD+1.0%+16.0%20.3%
CBLLCeriBell, Inc.LTM Mar 2026$11.68M USD+28.7%+34.5%12.3%
Peer median (excluding TOI) —+5.6%+23.7%62.1%

Competitors are the stored peer set for TOI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue203M252.48M324.24M393.41M502.73M
Cost of Revenue162.16M200.39M264.67M339.42M426.29M
Gross Profit40.85M52.09M59.57M54M76.44M
Gross Margin20.1%20.6%18.4%13.7%15.2%
Research & Development00000
Selling, General & Admin0000105.57M
Operating Expenses86.71M134.04M136.59M114.12M112.52M
Depreciation & Amortization3.34M4.41M5.87M6.29M6.94M
EBITDA(42.04M)(67.6M)(54.28M)(50.88M)(42.52M)
EBITDA Margin-20.7%-26.8%-16.7%-12.9%-8.5%
Operating Income(45.86M)(81.95M)(77.02M)(60.12M)(36.08M)
Operating Margin-22.6%-32.5%-23.8%-15.3%-7.2%
Interest Income00000
Interest Expense320K4.08M6.78M7.5M11.28M
Other Income / Expenses34.26M81.86M(6.09M)(4.55M)(24.65M)
Income Before Tax(11.6M)(91K)(83.1M)(64.66M)(60.74M)
Pre-Tax Margin-5.7%-0.0%-25.6%-16.4%-12.1%
Income Tax Expense(671K)(243K)(36K)0(131K)
Net Income(10.93M)152K(83.07M)(64.66M)(60.61M)
Net Margin-5.4%0.1%-25.6%-16.4%-12.1%
EPS (Basic)(0.16)0.00(0.92)(0.71)(0.54)
EPS (Diluted)(0.16)(0.21)(0.92)(0.71)(0.54)
Weighted Avg Shares66.23M72.79M73.75M75.04M923.89M
Weighted Avg Shares (Diluted)66.23M80.61M73.75M75.04M923.89M

The Oncology Institute, Inc.

NASDAQ:TOI

Intrinsic Alpha fair value

Locked

Current Price

$5.13

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.